Deutsche Bank Bears Lundbeck Amid Rexulti Challenges

Deutsche Bank has expressed a bearish outlook on Lundbeck, citing increasing challenges for its drug Rexulti. Specific issues impacting Rexulti's market performance were noted, although exact data points were not provided. The sentiment reflects concerns over potential impacts on Lundbeck's revenue, which could influence investor confidence. Given the ongoing headwinds for Rexulti, investors may need to reassess their positions regarding Lundbeck (LUN).